Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA-EP2006 versus Neulasta US and EU PK/PD similarity crossover study in healthy volunteers
NL-OMON45253Active, not recruiting
- Sponsor
- Hexal AG
- Start
- Apr 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of pegfilgrastim-bmez in neutropenia (3 arms), sponsored by Hexal AG. Primary endpoints: Pegfilgrastim AUC0-inf, Pegfilgrastim AUC0-last and 3 more. Started Apr 2017; status: active, not recruiting.
02
Drugs
pegfilgrastim-bmez
03
Conditions
neutropenia
Beyond the preview
Go deeper on NL-OMON45253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45253.